Arrowhead’s Planzirasan in FDA STAR Pilot Program for Severe HTG

Arrowhead Pharmaceuticals says the U.S. FDA has placed its drug candidate plozasiran into the agency’s STAR Pilot Program, a trial to shorten review times for an added indication of a drug already approved for other uses. The plan focuses on severe hypertriglyceridemia (sHTG), a condition linked with higher risk of pancreas inflammation and hospital visits. The STAR program is intended to speed up the review process if the supporting data suggest meaningful benefit over existing options.

What changed

The FDA granted entry into the STAR Pilot Program for Arrowhead’s planned supplemental NDA for plozasiran in treating severe hypertriglyceridemia. STAR stands for Split Real Time Application Review and is designed to shorten the time from a complete submission to an agency decision for specific drug indications tied to unmet medical needs. The company says this step is contingent on adequate and well-controlled evidence showing a substantial improvement on a clinically meaningful endpoint compared with current therapies.

Who is affected

Patients with severe hypertriglyceridemia (sHTG) are the primary group targeted by this development. sHTG increases the risk of acute pancreatitis, a painful and potentially life-threatening inflammation of the pancreas that can lead to hospitalizations. If approved, the sHTG indication would apply to people whose triglyceride levels are very high and who may not respond adequately to existing treatments.

Practical next steps for readers

What to watch for next includes: (1) the company’s submission timeline for the sNDA (supplemental NDA) for plozasiran focused on sHTG, (2) FDA communications about data demonstrating benefit versus current therapies. (3) updates on whether the STAR process results in an earlier decision date. Patients and clinicians should monitor official FDA announcements and company press releases for any changes to the program status, required monitoring plans, or safety information as data mature.

Limits and questions

Key questions remain about how quickly a decision might come under STAR, the exact clinical endpoints used to measure “substantial improvement,” and how the sHTG label would be defined if approved. The source notes that STAR requires robust evidence, but the timeline and final decision depend on the submitted data and FDA review dynamics. Readers should rely on official FDA and Arrowhead updates for precise details and avoid assumptions about approval timing or patient access until formal filings and decisions are announced.

Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.